Subretinal delivery of erythropoietin alleviates the N-methyl-N-nitrosourea-induced photoreceptor degeneration and visual functional impairments: an <i>in vivo</i> and <i>ex vivo</i> study

Tao, Ye; Wang, Yue; Ma, Zhao; Wang, Liqiang; Qin, Linling; Wang, Lu; Huang, Yi; Zhang, Shizhong

doi:10.1080/10717544.2017.1370620

Cited by 9 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of Bax was down-regulated at two weeks after injection in all rhEPO administrated groups and the expression of Bcl-2 was up-regulated. Our results demonstrated the anti-apoptotic effect of EPO, which were consistent with previous studies [11,27] . Furthermore, we made a comparison between rhEPO administration and rhEPO-hydrogel administration, nding that antiapoptotic effect of rhEPO-hydrogel administration group was better than that of the other group.…”

Section: Discussionsupporting

confidence: 93%

“…In recent years, EPO has become a safe and effective treatment for retinal disease. Beyond hematopoietic function, its anti-apoptosis and neuroprotective effect has also been proved [11,23] .…”

Section: Discussionmentioning

confidence: 99%

“…From many preclinical studies, EPO may become a useful agent for various ocular diseases [10] , for example, decreasing the apoptosis of RGCs in glaucoma, reducing retinal blood vessel degeneration to against the progression in diabetic retinopathy (DR), and preventing RPE apoptosis due to oxidative damage in age-related macular degeneration (AMD). A current study showed that subretinal injection of EPO could effectively alleviate photoreceptor degeneration of N-methyl-N-nitrosourea (MNU) administered mice [11] . This result indicated that EPO would become a potential therapeutic strategy in treating RP.…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Zhang

Dai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is the most common cause of blindness in retinal disease. Long-lasting ocular administration is an effective therapy to delay the progression of RP. And hydrogel sustained release system may be an available and stable drug carrier in the treatment of RP. Method Hydrogel sustained release system was constructed as a drug carrier of recombinant human erythropoietin (rhEPO). We administered retinal degenerative (rd) mice (Pdeb rd1 / Pdeb rd1 ) via subconjunctival or retrobulbar injection at postnatal 2 weeks (PN-2w), examined the mice and tested the factors of retina at two weeks after injection. Electroretinogram (ERG) was used to examine retinal function at PN-4w, western blot and q-PCR were used to test the expression of Bax, Bcl-2, iNOS and VEGFa of retina. Result Photoreceptor apoptosis were alleviated in all rhEPO administrated groups. The retinal blood supply was improved in injection groups. Compared with placebo and blank control groups, rhEPO treatment could enhance the retinal function and delay the progression of disease. Although there was no significant difference between rhEPO hydrogel and rhEPO treated group, photoreceptor apoptosis in rhEPO hydrogel group was less than that in rhEPO group, and the retinal function was better in rhEPO hydrogel group. Moreover, different routes of administration might have little effect on treatment in this research. Conclusion Early intervention can effectively control the progression of the disease. Anti-apoptosis,neuroprotection and erythropoietin of rhEPO could be useful in the treatment of RP. Hydrogel as a long-lasting drug sustained release system was stable and available, and might become a potential drug carrier in the future.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Zhang

Dai

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…Beyond hematopoietic function, its anti-apoptosis and neuroprotective effect has also been proved [11,23] .…”

Section: Discussionmentioning

confidence: 99%

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Zhang

Dai

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is the most common cause of blindness in retinal disease. Long-lasting ocular administration is an effective therapy to delay the progression of RP. And hydrogel sustained release system may be an available and stable drug carrier in the treatment of RP.Method Hydrogel sustained release system was constructed as a drug carrier of recombinant human erythropoietin (rhEPO). We administered retinal degenerative (rd) mice (Pdeb rd1 / Pdeb rd1 ) via subconjunctival or retrobulbar injection at postnatal 2 weeks (PN-2w), examined the mice and tested the factors of retina at two weeks after injection. Electroretinogram (ERG) was used to examine retinal function at PN-4w, western blot and q-PCR were used to test the expression of Bax, Bcl-2, iNOS and VEGFa of retina.Result Photoreceptor apoptosis were alleviated in all rhEPO administrated groups. The retinal blood supply was improved in injection groups. Compared with placebo and blank control groups, rhEPO treatment could enhance the retinal function and delay the progression of disease. Although there was no significant difference between rhEPO hydrogel and rhEPO treated group, photoreceptor apoptosis in rhEPO hydrogel group was less than that in rhEPO group, and the retinal function was better in rhEPO hydrogel group. Moreover, different routes of administration might have little effect on treatment in this research.Conclusion Early intervention can effectively control the progression of the disease. Anti-apoptosis,neuroprotection and erythropoietin of rhEPO could be useful in the treatment of RP. Hydrogel as a long-lasting drug sustained release system was stable and available, and might become a potential drug carrier in the future.

show abstract

Polyphenols and TBI

Forsan

2024

Nutritional Neurosciences

View full text Add to dashboard Cite

Subretinal delivery of erythropoietin alleviates the N-methyl-N-nitrosourea-induced photoreceptor degeneration and visual functional impairments: an in vivo and ex vivo study

Cited by 9 publications

References 47 publications

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Polyphenols and TBI

Contact Info

Product

Resources

About